In addition, given that topotecan is a topoisomerase I inhibitor that can induce DNA damage [31], we also investigated whether USP15 knockdown enhances topotecan‐induced DNA damage in NSCLC, as evaluated by immunofluorescence analysis of the damage marker γ‐H2AX. This evidence concerns the gene USP15 and non-small cell lung carcinoma.